April 2 (Reuters) - AC Immune SA ACIU.O:
AC IMMUNE SA - ACI-7104.056 IS WELL TOLERATED WITH NO SAFETY ISSUES REPORTED TO DATE
AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE
Source text: ID:nGNX6K9fwn
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.